Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Newbury Pharmaceuticals ABOSTO:NEWBRY -4.62%42 Current Ratio is 1.12 as of Feb. 2026, which is 49% below its 10-year median of 2.18. GuruFocus rates OSTO:NEWBRY with a GF Score™ of 42/100 and a GF Value™ of kr3.20 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 996 Drug Manufacturers companies, Newbury Pharmaceuticals AB ranks worse than 79.02% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Newbury Pharmaceuticals AB's current ratio for the quarter that ended in Feb. 2026 was 1.12.
Newbury Pharmaceuticals AB has a current ratio of 1.12. It generally indicates good short-term financial strength.
The historical rank and industry rank for Newbury Pharmaceuticals AB's Current Ratio or its related term are showing as below:
OSTO:NEWBRY'
s Current Ratio Range Over the Past 10 Years
Min: 1.12 Med: 2.18 Max: 6.19
Current: 1.12
During the past 5 years, Newbury Pharmaceuticals AB's highest Current Ratio was 6.19. The lowest was 1.12. And the median was 2.18.
OSTO:NEWBRY's Current Ratio is ranked worse than 79.02% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.925
vs OSTO:NEWBRY: 1.12
Newbury Pharmaceuticals AB (OSTO:NEWBRY) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Newbury Pharmaceuticals AB Current Ratio Related Terms
Newbury Pharmaceuticals AB Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NEWBRY vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a Current Ratio of 1.12 as of Feb. 2026. This is 49% below median its historical median of 2.18. Over the past decade, Newbury Pharmaceuticals AB's Current Ratio has ranged from 1.12 to 6.19. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #787 out of 996 companies in the Drug Manufacturers industry, placing it in the top 79%.
Is Newbury Pharmaceuticals AB's Current Ratio too high?
Newbury Pharmaceuticals AB's current Current Ratio of 1.12 is 49% below median its 10-year median of 2.18. Over the past 10 years, this metric has ranged from a low of 1.12 to a high of 6.19. The Drug Manufacturers industry median Current Ratio is 1.93. Newbury Pharmaceuticals AB's value of 1.12 is 41.8% below this industry median. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #787 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 42/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #787 out of 996 companies for Current Ratio. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median Current Ratio is 1.93. Newbury Pharmaceuticals AB's value of 1.12 is 41.8% below this benchmark. Historically, Newbury Pharmaceuticals AB's own Current Ratio has ranged from 1.12 to 6.19 over the past decade. While the company's 10-year median is 2.18 vs. the industry median of 1.93, Newbury Pharmaceuticals AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.93, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newbury Pharmaceuticals AB's current Current Ratio of 1.12 is 41.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current Current Ratio is 1.12, which is 49% below median its own 10-year median of 2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current Current Ratio is 1.12, which is 49% below median its 10-year median of 2.18 and 41.8% below the Drug Manufacturers industry median of 1.93. Newbury Pharmaceuticals AB's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current Current Ratio is 1.12 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20.
GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.
Key valuation signals for OSTO:NEWBRY:
Current Ratio: 1.12 (49% below median its 10-year median of 2.18)
GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
Industry Position: 41.8% below the Drug Manufacturers median (#787 of 996)
No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
42GF Score
Get the complete analysis for OSTO:NEWBRY
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NEWBRY has been successfully added to your 
